Synchronous Bilateral Talc Pleurodesis

Investigate feasibility of synchronous bilateral talc pleurodesis for malignant bilateral pleural effusions

Completed

Looking for future studies?

Key information

Conditions

Bilateral Pleural Effusion Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Pleural Diseases Pleural Effusion Pleural Effusion, Malignant Pleural Neoplasms Pleurodesis Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istituto Europeo di Oncologia

Milan, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 year-old
Patients undergoing synchronous bilateral talc pleurodesis
Diagnosis of malignant bilateral pleural effusions
Surgical resection between 1998 and September 2025

Exclusion criteria

Other type of surgery
Lack of consent to research
Other type of diagnosis (e.g. viral disease)

Treatment and study plan

Primary outcomes

postoperative mortality

Time frame: 35 years

Evaluation of postoperative complications occurred after talc pleurodesis.
postoperative morbidity

Time frame: 35 years

Evaluation of postoperative complications occurred after talc pleurodesis.

Sponsors and collaborators

Lead sponsor

European Institute of Oncology

Other

Registry information

Official study title

Synchronous Bilateral Talc Pleurodesis for Malignant Bilateral Pleural Effusions

Important dates

Study start: 1998
Primary completion: 2025
Study completion: 2025
First posted: Sep 9, 2026
Registry last updated: Sep 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed